+

WO2000070099A3 - Expression genique differente dans des regions specifiques du cerveau, dans des maladies neurodegeneratives - Google Patents

Expression genique differente dans des regions specifiques du cerveau, dans des maladies neurodegeneratives Download PDF

Info

Publication number
WO2000070099A3
WO2000070099A3 PCT/US2000/013951 US0013951W WO0070099A3 WO 2000070099 A3 WO2000070099 A3 WO 2000070099A3 US 0013951 W US0013951 W US 0013951W WO 0070099 A3 WO0070099 A3 WO 0070099A3
Authority
WO
WIPO (PCT)
Prior art keywords
contactin
present
neurodegenerative disease
compounds
compositions
Prior art date
Application number
PCT/US2000/013951
Other languages
English (en)
Other versions
WO2000070099A2 (fr
Inventor
Jung-Joo Hwang
K David Becker
Robert E Davis
Original Assignee
Mitokor
Hwang Jung Joo
K David Becker
Robert E Davis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitokor, Hwang Jung Joo, K David Becker, Robert E Davis filed Critical Mitokor
Priority to CA002371212A priority Critical patent/CA2371212A1/fr
Priority to JP2000618504A priority patent/JP2003504007A/ja
Priority to AU51503/00A priority patent/AU5150300A/en
Priority to EP00936142A priority patent/EP1208228A2/fr
Publication of WO2000070099A2 publication Critical patent/WO2000070099A2/fr
Publication of WO2000070099A3 publication Critical patent/WO2000070099A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L"invention concerne des molécules d"acide nucléique fonctionnant en tant qu"amorces de réaction PCR, dans la détection d"ARNm contactine, dans un échantillon. Il est possible de marquer ces molécules d"acide nucléique et de les préparer dans une trousse. L"invention concerne également un procédé de détection d"une maladie neurodégénérative, telle que la sclérose en plaques, ce procédé consistant à prélever un échantillon sur un patient, et à mesurer la quantité de protéine contactine ou d"ARNm contactine exprimée dans l"échantillon. L"invention concerne encore un procédé d"identification de patients souffrant d"une maladie neurodégénérative et susceptibles de répondre au traitement d"une telle maladie, de même que des compositions de matière comprenant une cellule isolée ou une cellule placée dans un culture qui exprime une quantité accrue ou diminuée de contactine par rapport à une cellule témoin. L"invention concerne aussi un procédé de criblage de composés, servant à mettre en évidence leur activité de réduction ou d"augmentation de l"expression de la contactine, ainsi que des compositions ou composés, notamment des compositions pharmaceutiques, identifiés à l"aide de ce procédé. On décrit encore des méthodes de traitement d"une maladie neurodégénérative à l"aide de tels composés ou compositions, ainsi que des procédés d"identification de cibles pharmaceutiques destinées à des composés modulant l"expression ou l"activité de la contactine, ainsi que des cibles identifiées à l"aide de tels procédés.
PCT/US2000/013951 1999-05-19 2000-05-19 Expression genique differente dans des regions specifiques du cerveau, dans des maladies neurodegeneratives WO2000070099A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002371212A CA2371212A1 (fr) 1999-05-19 2000-05-19 Expression genique differente dans des regions specifiques du cerveau, dans des maladies neurodegeneratives
JP2000618504A JP2003504007A (ja) 1999-05-19 2000-05-19 神経変性性疾患における脳の特異的な領域での異なる遺伝子発現
AU51503/00A AU5150300A (en) 1999-05-19 2000-05-19 Differential gene expression in specific regions of the brain in neurodegenerative diseases
EP00936142A EP1208228A2 (fr) 1999-05-19 2000-05-19 Expression genique differente dans des regions specifiques du cerveau, dans des maladies neurodegeneratives

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13479099P 1999-05-19 1999-05-19
US60/134,790 1999-05-19
US57461300A 2000-05-18 2000-05-18
US09/574,613 2000-05-18

Publications (2)

Publication Number Publication Date
WO2000070099A2 WO2000070099A2 (fr) 2000-11-23
WO2000070099A3 true WO2000070099A3 (fr) 2002-04-04

Family

ID=26832668

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/013951 WO2000070099A2 (fr) 1999-05-19 2000-05-19 Expression genique differente dans des regions specifiques du cerveau, dans des maladies neurodegeneratives

Country Status (5)

Country Link
EP (1) EP1208228A2 (fr)
JP (1) JP2003504007A (fr)
AU (1) AU5150300A (fr)
CA (1) CA2371212A1 (fr)
WO (1) WO2000070099A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001069261A2 (fr) * 2000-03-15 2001-09-20 Oxford Glycosciences (Uk) Ltd. Proteines, genes et leur utilisation dans le diagnostic et le traitement de la demence vasculaire
AU2002239531A1 (en) * 2000-11-08 2002-05-27 Mitokor Differential gene expression in specific regions of the brain in neurodegenerative diseases
ATE394115T1 (de) 2001-02-27 2008-05-15 Brni Neurosciences Inst Diagnose der alzheimer-krankheit auf basis von mitogenaktivierter proteinkinase-phosphorylierung
WO2003023056A2 (fr) * 2001-09-12 2003-03-20 F. Hoffmann-La Roche Ag Marqueurs specifiques a la sclerose en plaques
EP1497661B1 (fr) * 2002-04-24 2009-11-25 EVOTEC Neurosciences GmbH Utilisation a des fins diagnostiques du gene et de la proteine ensadine-0477 pour le traitement de maladies neurodegeneratives
EP1587960A2 (fr) * 2003-01-30 2005-10-26 Research Development Foundation Procedes et compositions d'analyse de l'expression genique liee a la mitochondrie
CA2582270A1 (fr) * 2004-11-15 2006-05-26 Blanchette Rockefeller Neurosciences Institute Anomalies de la phosphatase 2a (pp2a) pour le diagnostic et le traitement de la maladie d'alzheimer
US20090029873A1 (en) 2005-10-11 2009-01-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb)
US8252540B2 (en) 2007-08-03 2012-08-28 Keio University Drug delivery system toward demyelinating lesion and biochemical marker of demyelinating lesion
US8822166B2 (en) 2008-07-28 2014-09-02 Blanchette Rockefeller Neurosciences Institute Stimulus-elicited genomic profile markers of alzheimer's disease
US8163800B2 (en) 2008-07-28 2012-04-24 Blanchette Rockefeller Neurosciences Institute PKC-activating compounds for the treatment of neurodegenerative diseases
WO2011041761A1 (fr) 2009-10-02 2011-04-07 Blanchette Rockefeller Neurosciences Institute Profils de croissance de fibroblastes pour le diagnostic de la maladie d'alzheimer
WO2013071281A1 (fr) 2011-11-13 2013-05-16 Blanchette Rockefeller Neurosciences Institute Esters de dcpla et méthodes de traitement les utilisant

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995035373A2 (fr) * 1994-06-10 1995-12-28 La Jolla Cancer Research Foundation Molecules d'acide nucleique codant la contactine humaine
WO1997015690A1 (fr) * 1995-10-24 1997-05-01 Curagen Corporation Procede et dispositif d'identification, de classification ou de denombrement de sequences d'adn dans un echantillon sans sequençage
US5739289A (en) * 1993-03-26 1998-04-14 Becton, Dickinson And Company Monoclonal antibody to human cell adhesion molecule
WO1998049342A1 (fr) * 1997-04-30 1998-11-05 Forskningsparken I Ås As Procede servant a preparer un type standard de produit de transcription genetique de diagnostic
US5888498A (en) * 1995-03-03 1999-03-30 Mitokor Cellular and animal models for diseases associated with mitochondrial defects

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739289A (en) * 1993-03-26 1998-04-14 Becton, Dickinson And Company Monoclonal antibody to human cell adhesion molecule
WO1995035373A2 (fr) * 1994-06-10 1995-12-28 La Jolla Cancer Research Foundation Molecules d'acide nucleique codant la contactine humaine
US5888498A (en) * 1995-03-03 1999-03-30 Mitokor Cellular and animal models for diseases associated with mitochondrial defects
WO1997015690A1 (fr) * 1995-10-24 1997-05-01 Curagen Corporation Procede et dispositif d'identification, de classification ou de denombrement de sequences d'adn dans un echantillon sans sequençage
WO1998049342A1 (fr) * 1997-04-30 1998-11-05 Forskningsparken I Ås As Procede servant a preparer un type standard de produit de transcription genetique de diagnostic

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PLAGGE A ET AL: "The gene of the neural cell recognition molecule F11: conserved exon-intron arrangement in genes of neural members of the immunoglobulin superfamily", GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, ELSEVIER SCIENCE PUBLISHERS, BARKING, GB, vol. 192, no. 2, 1997, pages 215 - 225, XP004081714, ISSN: 0378-1119 *
SHIMAZAKI K ET AL: "Age-related decline of f3/contactin in rat hippocampus", NEUROSCIENCE LETTERS, vol. 245, no. 2, 1998, pages 117 - 20, XP001024403 *

Also Published As

Publication number Publication date
AU5150300A (en) 2000-12-05
JP2003504007A (ja) 2003-02-04
WO2000070099A2 (fr) 2000-11-23
EP1208228A2 (fr) 2002-05-29
CA2371212A1 (fr) 2000-11-23

Similar Documents

Publication Publication Date Title
Condliffe et al. Cross-region reduction in 5-hydroxymethylcytosine in Alzheimer's disease brain
Nakano et al. Homologous recombination but not nucleotide excision repair plays a pivotal role in tolerance of DNA-protein cross-links in mammalian cells
Haghdoost et al. The nucleotide pool is a significant target for oxidative stress
Zhu et al. MicroRNA-494 improves functional recovery and inhibits apoptosis by modulating PTEN/AKT/mTOR pathway in rats after spinal cord injury
Vannini et al. Effects of a complex mixture of therapeutic drugs on unicellular algae Pseudokirchneriella subcapitata
Goto et al. Yeast DNA topoisomerase II. An ATP-dependent type II topoisomerase that catalyzes the catenation, decatenation, unknotting, and relaxation of double-stranded DNA rings.
Phay et al. Analysis of piRNA-like small non-coding RNAs present in axons of adult sensory neurons
US10550426B2 (en) Method for detecting methylated DNA
WO2000070099A3 (fr) Expression genique differente dans des regions specifiques du cerveau, dans des maladies neurodegeneratives
CN110791560B (zh) 一种用于阿尔茨海默病诊断和/或治疗的miRNA标志物
Kumar et al. Tet1 oxidase regulates neuronal gene transcription, active DNA hydroxymethylation, object location memory, and threat recognition memory
Liu et al. PARP-1 enhances the mismatch-dependence of 5′-directed excision in human mismatch repair in vitro
WO2006096737A3 (fr) Cible diagnostique et therapeutique pour degenerescence maculaire
Sarasin et al. New insights for understanding the transcription-coupled repair pathway
Rezende et al. Knock out of the NADPH oxidase Nox4 has no impact on life span in mice
Guo et al. Genome-wide antagonism between 5-hydroxymethylcytosine and DNA methylation in the adult mouse brain
WO2010011283A3 (fr) Composés à base de fus/tls et méthodes de diagnostic, traitement et prévention d'une sclérose latérale amyotrophique et de maladies des motoneurones apparentées
de Melo et al. XPC deficiency is related to APE1 and OGG1 expression and function
Mukai et al. Recombinant mammalian tubulin polyglutamylase TTLL7 performs both initiation and elongation of polyglutamylation on β-tubulin through a random sequential pathway
AU2016282350A1 (en) Targeted enrichment of long nucleotide sequences using microfluidic partitioning
US11359245B2 (en) Method for determining decrease in functions of hippocampus by using correlation between micro RNA and NMDA receptor, method for inhibiting decrease in functions, and method for screening for inhibitors of decrease in functions
JP2010535501A (ja) チオプリン薬抵抗性およびチオプリン薬不耐性のリスクがある個体を同定する方法
Rybin et al. Emerging technologies for genome-wide profiling of DNA breakage
Trotzier et al. Phosphorylation of ICBP90 by protein kinase A enhances topoisomerase IIα expression
Vindry et al. A homozygous mutation in the human selenocysteine tRNA gene impairs UGA recoding activity and selenoproteome regulation by selenium

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2371212

Country of ref document: CA

Ref country code: CA

Ref document number: 2371212

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 51503/00

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 618504

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000936142

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000936142

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000936142

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载